Connect with us

Technology

JuveXO® Unveils Verified Exosome Images, Setting a New Standard in Transparency and Scientific Proof in Cosmetics

Published

on

MIAMI, April 22, 2025 /PRNewswire/ — The scientific team at JuveXO®, one of the most advanced exosome-based solutions available today, is thrilled to announce the first images of exosomes – an incredible achievement that positions JuveXO® at the forefront of biocosmetic discovery. Born from decades of research and innovation by Chief Development & Science Officer (CDSO) Rafael Gonzalez, PhD, a leading figure in cell therapy research, and the scientists behind JuveXO® have fully characterized their exosomes and gone above and beyond to show off their superior exosome product. JuveXO boasts billions of exosomes in each of its vials as well as naturally occurring High Molecular Weight Hyaluronic Acid, Collagen I and III, Glutathione, Biotin, Peptides, and Growth Factors. JuveXO is used topically for hair and skin rejuvenation post aesthetic treatments such as microneedling, RF (radiofrequency) laser, CO2 laser, hair restoration procedures, and chemical peels, enhancing recovery and optimizing results. https://juvexo.com/blogs/articles/breaking-ground-juvexos-first-image-of-an-exosome-a-new-era-in-scientific-visualization

JuveXO® releases verified exosome images—setting a new benchmark for scientific proof in aesthetics.

But first, what are exosomes? Exosomes are small extracellular vesicles that play a pivotal role in intercellular communication, serving as vehicles for the transport of various biomolecules such as proteins, lipids, and nucleic acids between cells. Exosome technology has garnered significant attention in recent years due to their multifaceted functions and profound implications. JuveXO® is the first biocosmetic company to image exosomes both in frozen vials and following lyophilization using advanced electron microscopy techniques, the correct approach to visualizing an exosome and demonstrating its presence. The ability to visualize exosomes with such precision gives JuveXO® a significant competitive advantage over other players in the biocosmetic sector.

With research on optimal biocosmetic formulations stemming back to 2014, JuveXO® stands out as a distinctive scientific leader in the rapidly evolving field of biocosmetics space. JuveXO®’s umbilical cord lining stem cells (ULSCs) are superior to a standard MSC, were specifically researched and designed for the biocosmetic space—offering optimal results for the skin. 

Chief Development & Science Officer (CDSO) Rafael Gonzalez, PhD of JuveXO® says, “It’s a groundbreaking time for all of us at JuveXO® who have dedicated so much research, time and resources perfecting our product. The ability to visualize exosomes with such precision gives JuveXO® a significant competitive advantage over other players in the biocosmetic and aesthetic sectors. The imaging technology that JuveXO® employs represents a significant leap forward in the field of aesthetics, enabling practitioners to see that the product truly does contain exosomes. This helps them trust the products they are providing to patients.”

While the ability to visualize exosomes decades ago marked a significant breakthrough in biomedical research for new scientific innovations, many exosome-derived products lacked rigorous validation until recently. Adopting advanced imaging methods has allowed researchers at JuveXO® to deepen their understanding of the exosome. Today, as numerous brands enter the market with claims of including exosomes in their products, the leaders at Congela Biocosmetics, the distributor of JuveXO, are raising the bar for industry transparency. By conclusively proving the presence of exosomes in our products, we invite others to meet this new standard of verification. Our message to the industry is straightforward: “We’ve shown you ours, now you show us yours.”

To prove their presence and integrity in products, JuveXO® has embraced the standards set by the International Society for Extracellular Vesicles (ISEV), which recommends specific techniques for confirming exosome presence, such as nanoparticle tracking analysis, tunable resistive pulse sensing, and electron microscopy amongst other marker expressions that need to be present. Electron microscopy, specifically, allows for the direct observation of exosomes, showcasing their size, shape, and the integrity of their bilipid layers, which are crucial for their functionality.

Utilizing state-of-the-art equipment and methodologies, researchers can accurately observe exosomes on a nanoscale level, pinpointing their presence and concentration in biological samples that lead to deeper scientific insights. By adhering to these ISEV-endorsed techniques and especially employing electron microscopy, JuveXO® not only substantiates the presence of genuine exosomes in their products but also ensures they remain intact and functional from production to delivery. This adherence to the highest scientific standards establishes a new benchmark in product transparency and trust, pioneering a standard that should define the future of regenerative medicine and cosmetic industries alike.

ABOUT JuveXO®
JuveXO® is a high-quality umbilical cord lining stem cell (ULSCs) product that is superior to standard MSC-derived secretome products. We have a patent-pending technology that enables control of the protein type released by ULSCs. With more than ten years of research, JuveXO® has been specially designed to contain high amounts of naturally occurring Types I and III Collagen, Biotin, Gluthathione, Chondroitin Sulfate, Growth Factors, and High-Molecular-Weight Hyaluronic Acid, making JuveXO® the leader in cosmetic use. Our premium serum line is produced from vigorously tested, postnatal ULSCs and is pre-COVID and cell-free. JuveXO® offers a comprehensive exosome portfolio, including:

JuveXO® Pro – A multi-dose vial designed for professional aesthetic skincare treatments that boasts 50 billion exosomes per mL.JuveXO® Pro H – Developed specifically for scalp and hair restoration applications with 50 billion exosomes per mL.JuveXO® Lyo – A lyophilized formula with 25 billion exosomes per vial that can be reconstituted to service up to 5 patients, offering greater flexibility and convenience.

JuveXO products are developed in an FDA-registered laboratory which follows good manufacturing practices, ensuring the highest standards of quality, safety, and compliance. Our commitment to excellence is underscored by adherence to rigorous regulatory standards and ethical practices, providing practitioners and consumers with trusted and effective biocosmetic solutions. To find a provider near you, visit JuveXO.com. If you are a physician interested in becoming a provider, visit https://juvexo.com/account/register.

For more information or interviews requests, please contact:
Creative Media Marketing | juvexo@cmmpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/juvexo-unveils-verified-exosome-images-setting-a-new-standard-in-transparency-and-scientific-proof-in-cosmetics-302433763.html

SOURCE JuveXO®

Continue Reading

Technology

Ascendion Expands AI Advisory Community with Four Global Business and Technology Leaders

Published

on

By

Former Global CTO of Banco Santander, former Group CIO of Currys, former CEO of IBPAP, and former Microsoft CVP and CTO of AI join the advisory community

Advisors will provide guidance on AAVA platform innovation, AI strategy, C-suite alignment, and enterprise adoption across Asia-Pacific, Europe, North America, and the UK

The growing community of advisors will bring practitioner perspective closer to Ascendion as enterprises move AI from experimentation to governed, production-scale outcomes

BASKING RIDGE, N.J., Oct. 27, 2026 /PRNewswire/ — Ascendion, an AI-native software engineering company, today announced the appointment of four global business and technology leaders to its AI Advisory Community: Andy Gamble, Jack Madrid, Julieta Ross, Ph.D., and Joseph Sirosh, Ph.D. 

The advisors bring perspectives rarely found in one group: executives who answered to Boards, regulators, and C-suites for what technology actually delivered; a builder of AI and data platforms at global scale; and a leader who shaped one of the world’s largest technology-services and talent ecosystems. Their experience spans banking, high-tech, media, and retail. Each will work directly with Ascendion’s regional and engineering leaders, so their counsel reaches the decisions it is meant to shape. 

“We are changing how software gets built. Enterprise leaders have moved past experiments. They want AI that delivers outcomes boards can measure and risk they can manage. Andy, Jack, Julieta, and Joseph have the experience and know where transformation succeeds. They will challenge our thinking, raise our ambition, and help us navigate a period of intense — and exciting — change,” said Karthik Krishnamurthy, CEO, Ascendion. 

Each advisor will map to a different part of the business, strengthening Ascendion’s alignment with leadership communities across the globe. 

Julieta Ross, Ph.D., former Global CTO of Banco Santander, brings two decades of leading technology inside global banks, along with public-company board experience. She will work with Ascendion’s leadership on executive relationships, go-to-market strategy, and growth, and will help the company meet the governance, regulatory, and risk expectations that banking and financial services leaders place on AI. Andy Gamble, former Group CIO of Currys plc, has spent nearly three decades as a technology buyer and transformation leader across consumer electronics, industrial, and retail businesses. He will advise Ascendion’s work across Europe and the UK, with a focus on consumer goods, manufacturing, and retail, and will share what executive teams and Boards expect from a technology partner. Joseph Sirosh, Ph.D., former Microsoft CVP and CTO of AI, has spent his career building and scaling machine learning platforms in the high-tech industry. He will advise Ascendion’s engineering leadership on the evolution of AAVA and its broader platform strategy as AAVA becomes an orchestration and harness layer for enterprise AI. Jack Madrid, former President and CEO of IBPAP, spent five years leading the industry association behind one of the world’s largest technology and business-services ecosystems, centered in the Philippines. He brings robust experience working across industries, including banking, high-tech, and media, and will advise Ascendion on Asia-Pacific markets and on how AI is reshaping global delivery, skills, and workforce models. 

Together, the advisors give Ascendion an outside perspective on the full spectrum of enterprise AI, from agentic platform strategy and product engineering to industry alignment and delivery. They will add capacity to Ascendion’s ongoing work on AI governance, helping ensure trusted impact from AI-native software engineering, and their practice-based insight will inform how Ascendion applies its Engineering to the Power of AI™ approach to commercial models, platform design, service execution, and workforce development. 

About Ascendion

Ascendion is a global AI-native software engineering company delivering trusted business outcomes – capital unlock, innovation velocity, lower risk – to 250+ enterprise clients. The company delivers business outcomes at scale by combining expert engineers, AI agents, and AAVA, Ascendion’s agentic AI platform. Together, they design, engineer, and operate production-ready software that improves everyday work and life. Learn more at www.ascendion.com.

Engineering to the Power of AI™, Engineering to Elevate Life™, and AAVA™ are trademarks or service marks of Ascendion. AAVA™ is pending registration. Unauthorized use is strictly prohibited.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ascendion-expands-ai-advisory-community-with-four-global-business-and-technology-leaders-302921368.html

Continue Reading

Technology

AvePoint Set to Join S&P SmallCap 600

Published

on

By

NEW YORK, Oct. 27, 2026 /PRNewswire/ — AvePoint Inc. (NASD: AVPT) will replace LXP Industrial Trust (NYSE: LXP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 2. Brookfield Asset Management Ltd. and Canada Pension Plan Investment Board are acquiring LXP Industrial Trust in a deal expected to close soon, pending final closing conditions.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name

Action

Company Name

Ticker

GICS Sector

Nov 2, 2026

S&P SmallCap 600

Addition

AvePoint

AVPT

Information Technology

Nov 2, 2026

S&P SmallCap 600

Deletion

LXP Industrial Trust

LXP

Real Estate

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/avepoint-set-to-join-sp-smallcap-600-302921327.html

SOURCE S&P Dow Jones Indices

Continue Reading

Technology

Archera Surpasses $5.6 Billion in Cloud and AI Spend Under Management, Closes Series C Led by Pivot Investment Partners, and Expands Insurance-Backed Cloud Commitments

Published

on

By

The round will help Archera expand its guaranteed cloud commitments, bringing insurance-backed financial protection to companies navigating unpredictable AI and cloud spending. The company has delivered more than $700 million in customer savings and now manages approximately $5.6 billion in annual cloud and AI spend.

BELLEVUE, Wash., Oct. 27, 2026 /PRNewswire/ — As artificial intelligence makes cloud spending harder to predict, companies face an increasingly expensive choice: commit to long-term cloud and AI contracts to unlock significant discounts or preserve flexibility and leave savings on the table. Archera has raised a $15 million Series C to expand its Guaranteed Commitments and change that equation.

The cloud economics company today announced it closed its Series C funding round, led by Pivot Investment Partners, with participation from existing investors including HighSage Ventures. The financing brings Archera’s total funding to $38.3 million. It will support the expansion of Archera’s Guaranteed Commitments and its suite of free cloud cost tools, including its FinOps Agent and MCP.

Insurance-backed financial protection is central to Archera’s next phase of growth. Archera purchased a policy on a surplus lines basis from Crum & Forster Specialty Insurance Company to back its guarantee. This model helps businesses pursue cloud commitment savings while managing the financial risk of usage changes.

The company has delivered more than $700 million in savings to over 2,200 organizations, including PubNub, Art.com, and Astronomer. The thesis behind Archera is simple: companies shouldn’t have to predict AI’s future to commit and save money on today’s infrastructure.

Why Cloud and AI Commitments Need to Change

Cloud providers reward customers who commit to spending over one- to three-year periods with substantial discounts and access to capacity. Historically, those commitments have helped businesses reduce infrastructure costs. But AI is changing the risk and economics of that decision.

A new model launch can multiply GPU spending in months. A more efficient model, a shift in architecture, or a move to a different service can reduce it just as quickly. Long-term commitments that once looked financially sound can become expensive liabilities.

Companies are left choosing between overcommitting and risking unused spend, or undercommitting and missing out on available discounts. Many choose the latter, sacrificing potential savings to preserve flexibility.

Archera believes that the trade-off is unnecessary. Its Guaranteed Commitments provide resource-level cloud and AI discounts with terms as short as 30 days. If usage declines and a covered commitment goes unused, Archera covers the cost under the terms of its guarantee.

The result is a different way to approach cloud purchasing. Businesses can pursue deeper discounts and unlock capacity otherwise gated behind a commitment, without bearing the entire financial consequence when actual usage diverges from forecasts.

Turning Cloud Optimization Into a Financial Product

Traditional cloud cost management tools provide visibility, recommendations, automation, and forecasting, but they can’t eliminate the financial risk of unused commitments. Archera combines its free FinOps platform and Agent with a financial guarantee that addresses inaccurate forecasts.

“Every tool in this market is trying to forecast your cloud usage a little better. We think that’s the wrong bet,” said Aran Khanna, co-founder and CEO of Archera. “Nobody can forecast AI demand, not the customer, not the cloud provider. So instead of predicting it, we guarantee it, and we have purchased an insurance policy to back that guarantee. If covered usage drops, we address the unused commitment cost under the terms of our guarantee. That’s a new way to purchase cloud, not another dashboard, and it’s why we’ve been able to return $700 million to our customers.”

The approach positions cloud commitments as a financial risk decision, helping finance and engineering leaders manage budgets while adapting to changing technology.

Built for CFOs, CTOs, and the Teams Managing AI Costs

The approach addresses a growing challenge across finance and engineering: how to control infrastructure costs without constraining the business.

For CFOs: Capture commitment-level discounts while reducing exposure to eligible unused spend under the guarantee.For CTOs and engineering leaders: Preserve flexibility to adopt new AI models, change architectures, and scale workloads without letting past commitments dictate future decisions.For FinOps teams: Increase commitment coverage with a financial backstop when usage changes, without more back-and-forth with engineering teams to get perfect forecasts.For cloud partners and resellers: Give customers a differentiated way to pursue cloud savings that can be reinvested in new cloud services while managing commitment risk.

Archera’s platform connects to AWS, Microsoft Azure, or Google Cloud billing data in read-only mode and analyzes actual usage. It then recommends and automates the purchasing of both native commitments and Archera Guaranteed Commitments.

Customers can evaluate their potential savings before making any purchasing decision. Commitments remain in the customer’s own cloud account, preserving end-to-end control over cloud purchasing strategy.

Archera earns when customers save through its guaranteed commitments, aligning its commercial model with the outcomes customers seek.

Customers Are Rethinking the Commitment Model

For organizations accustomed to treating cloud commitments as a single, high-stakes decision, Archera offers a more flexible approach.

“Working with Archera meant rethinking commitments as a spectrum rather than a single, high-stakes decision,” said James Hamilton, VP of Operations and Controller at PubNub. “This was a big mind shift for us. We needed to think about how our commitments could be broken up into a spectrum of purchases versus a single one-time buy.”

That flexibility is particularly valuable as companies adopt AI workloads, where technology choices and resource requirements can shift faster than traditional budgeting cycles.

Instead of making one large bet on future usage, businesses can take a more measured approach while still securing meaningful discounts.

A Series C to Expand Insurance-Backed Cloud Purchasing

Archera has been operating profitably at scale. It raised a Series C to support larger guarantees, expand its reach, serve more customers, and upgrade the insurance policies backing its guarantee to serve larger global clients.

The company plans to use the capital in three ways:

Accelerate go-to-market efforts.Expand its global partner network across North America, Europe, the Middle East, Japan, and Latin America.Serve more teams focused on AI-driven workloads.

“Archera has built a capital-efficient and differentiated business at the intersection of cloud infrastructure and risk management,” said Dinkar Jetley, co-founder and managing partner at Pivot Investment Partners. “The team pairs a deep understanding of the cloud ecosystem with a rigorous approach to underwriting, and the result is a compelling value proposition that a fast-growing roster of customers relies on as their cloud spend scales. We are privileged to have led this Series C round and look forward to working closely with Aran and the management team in the years ahead.”

Built by People Who Understand Cloud Infrastructure

Aran and Nikhil Khanna founded Archera in 2019. Aran previously planned capacity for Azure’s core compute and database services at Microsoft and was a founding member of AWS’s deep learning team leading launches, including SageMaker, DeepLens, and the Neuron SDK, behind Amazon’s Trainium and Inferentia AI chips.

His research on deep learning model efficiency has been cited more than 1,900 times, and he serves on the FinOps Foundation governing board.

As AI transforms infrastructure economics, Archera aims to make cloud savings more accessible without forcing businesses to assume unnecessary financial risk.

To explore potential savings, request a free assessment at Archera.ai.

Free savings assessment: https://app.archera.ai/savings-estimate?utm_source=forbes&utm_medium=referral&utm_campaign=series-c-2026

Name: Sarah
Email Address: shiara@archera.ai
Phone Number: +13018255007

View original content to download multimedia:https://www.prnewswire.com/news-releases/archera-surpasses-5-6-billion-in-cloud-and-ai-spend-under-management-closes-series-c-led-by-pivot-investment-partners-and-expands-insurance-backed-cloud-commitments-302921341.html

SOURCE Archera

Continue Reading

Trending